Detection of Parkinson’s disease (PD) traditionally has never been an exact science, as many diagnoses rely on the classification of various symptoms and behavioral anomalies. However, several other neurological disorders present with very similar symptomology as PD but have entirely different clinical outcomes and treatment regimens. In recent years, scientists have searched for specific DNA and protein biomarkers that would provide them with a clear indication that a patient had PD. This approach has met with some success, yet most often clinicians need to obtain cerebrospinal fluid samples from patients through invasive and uncomfortable techniques.
